Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EPS (Weighted Average and Diluted) (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$2.01 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 84.66% to -$2.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.69, a 58.5% increase, with the full-year FY2025 number at -$2.45, up 88.3% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$2.01 in Q4 2025 for Aligos Therapeutics, up from -$3.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.81 in Q2 2024 to a low of -$13.1 in Q4 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.84 (2022), compared with a mean of -$2.57.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 288.37% in 2024, down 3458.97% in 2024.
  • Aligos Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.78 in 2021, then soared by 34.62% to -$0.51 in 2022, then skyrocketed by 176.47% to $0.39 in 2023, then crashed by 3458.97% to -$13.1 in 2024, then skyrocketed by 84.66% to -$2.01 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$2.01 (Q4 2025), -$3.04 (Q3 2025), and -$1.53 (Q2 2025) per Business Quant data.